Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The companies press on with vilastobart and IMPT-314... up to a point.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
